4. (Amended) The method of claim 1 wherein said immunostimulatory dosage is about 500 U/m^2 to about 500,000 U/m^2 per day [or less].

5. (Amended) The method of claim 1 wherein said immunostimulatory dosage is about 500 U/m^2 to about 250,000 U/m^2 per day [or less].

6. (Amended) The method of claim 1 wherein said immunostimulatory dosage is about 500 U/m^2 to about 100,000 U/m^2 per day [or less].

23. (Twice Amended) A method for [preventing post-operative infection] stimulating the immune system of a patient prior to undergoing surgery, said method comprising administering an immunostimulatory dosage of an α-interferon composition to [a human] said patient before surgery, wherein said immunostimulatory dosage is about 500 U/m^2 to about 4,000,000 U/m^2 per day [or less], and wherein said immunostimulatory dosage reduces post-operative infections in said patient.

24. (Twice Amended) An article of manufacture comprising packaging material and an α-interferon composition contained within said packaging material, wherein said packaging material comprises a label or package insert indicating that administration of an immunostimulatory dosage of said α-interferon composition followed by surgical resection of a malignant tumor [can be] is effective for [treating] stimulating the immune system of a human patient having said malignant tumor, wherein said immunostimulatory dosage is about 500 U/m^2 to about 4,000,000 U/m^2 per day [or less].

25. (Twice Amended) An article of manufacture comprising packaging material and an α-interferon composition contained within said packaging material, wherein said packaging material comprises a label or package insert indicating that administration of an immunostimulatory dosage of said α-interferon composition in conjunction with treating said patient [using] with effective non-surgical medical methodologies for diminishing said malignant tumor [can be] is effective for [treating] stimulating the immune system of a human patient